{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:06:36Z","timestamp":1785859596989,"version":"3.56.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,3,15]]},"DOI":"10.1097\/01.tp.0000191291.71003.1b","type":"journal-article","created":{"date-parts":[[2006,3,9]],"date-time":"2006-03-09T05:27:48Z","timestamp":1141882068000},"page":"767-772","source":"Crossref","is-referenced-by-count":43,"title":["An Open Prospective Pilot Study on the Use of Rapamycin after Penetrating High-Risk Keratoplasty"],"prefix":"10.1097","volume":"81","author":[{"given":"Florian","family":"Birnbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"B\u00f6hringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgenia","family":"Sokolowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Voiculescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Sundmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reinhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210129","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/0002-9394(89)90494-7","article-title":"The use of cyclosporine in high-risk keratoplasty.","volume":"107","author":"Hill","year":"1989","journal-title":"Am J Ophthalmol"},{"key":"R2-19-20210129","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0161-6420(13)31253-6","article-title":"Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy.","volume":"101","author":"Hill","year":"1994","journal-title":"Ophthalmology"},{"key":"R3-19-20210129","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-2008-1035032","article-title":"[Acute and chronic immune reactions after penetrating keratoplasty with normal immune risk].","volume":"210","author":"Reinhard","year":"1997","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"R4-19-20210129","first-page":"705","article-title":"[Allograft rejection reactions after keratoplasty (author\u2019s transl)].","volume":"171","author":"Sundmacher","year":"1977","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"R5-19-20210129","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.TP.0000158022.62059.F2","article-title":"Immunosuppression with cyclosporine a and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study.","volume":"79","author":"Birnbaum","year":"2005","journal-title":"Transplantation"},{"key":"R6-19-20210129","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s003470050146","article-title":"[Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor].","volume":"94","author":"Reinhard","year":"1997","journal-title":"Ophthalmologe"},{"key":"R7-19-20210129","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s004170100285","article-title":"Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years\u2019 results of a randomized prospective clinical trial.","volume":"239","author":"Reinhard","year":"2001","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R8-19-20210129","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1432-2277.2005.00126.x","article-title":"Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study.","volume":"18","author":"Reinhard","year":"2005","journal-title":"Transpl Int"},{"key":"R9-19-20210129","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/bjo.83.11.1268","article-title":"Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial.","volume":"83","author":"Reis","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"R10-19-20210129","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/00007890-200011150-00022","article-title":"Coadministration of the new macrolide immunosuppressant RAD and mycophenolate mofetil in experimental corneal transplantation.","volume":"70","author":"Reis","year":"2000","journal-title":"Transplantation"},{"key":"R11-19-20210129","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s004170100258","article-title":"RAD, a new immunosuppressive macrolide in murine corneal transplantation.","volume":"239","author":"Reis","year":"2001","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R12-19-20210129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00003226-200201000-00017","article-title":"Synergism of RAD and cyclosporin A in prevention of acute rat corneal allograft rejection.","volume":"21","author":"Reis","year":"2002","journal-title":"Cornea"},{"key":"R13-19-20210129","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"R14-19-20210129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.","volume":"71","author":"MacDonald","year":"2001","journal-title":"Transplantation"},{"key":"R15-19-20210129","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/jlts.2001.26510","article-title":"Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.","volume":"7","author":"McAlister","year":"2001","journal-title":"Liver Transpl"},{"key":"R16-19-20210129","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1034\/j.1600-6143.2002.20507.x","article-title":"Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.","volume":"2","author":"Morales","year":"2002","journal-title":"Am J Transplant"},{"key":"R17-19-20210129","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.rmed.2003.12.016","article-title":"Role of sirolimus, a novel immunosuppressive drug in heart and lung transplantation.","volume":"98","author":"Shitrit","year":"2004","journal-title":"Respir Med"},{"key":"R18-19-20210129","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"R19-19-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.2610140102","article-title":"Rapamycin: a novel immunosuppressive macrolide.","volume":"14","author":"Sehgal","year":"1994","journal-title":"Med Res Rev"},{"key":"R20-19-20210129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4615-1809-9_5","article-title":"Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells.","volume":"1","author":"Wiederrecht","year":"1995","journal-title":"Prog Cell Cycle Res"},{"key":"R21-19-20210129","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1161\/01.RES.76.3.412","article-title":"Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells.","volume":"76","author":"Marx","year":"1995","journal-title":"Circ Res"},{"key":"R22-19-20210129","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0041-1345(98)00107-9","article-title":"High local production of nitric oxide as a possible mechanism by which rapamycin prevents transplant arteriosclerosis.","volume":"30","author":"Pham","year":"1998","journal-title":"Transplant Proc"},{"key":"R23-19-20210129","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1097\/01.TP.0000120181.89206.54","article-title":"Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.","volume":"77","author":"Guba","year":"2004","journal-title":"Transplantation"},{"key":"R24-19-20210129","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1097\/00007890-200205270-00008","article-title":"Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy.","volume":"73","author":"Luan","year":"2002","journal-title":"Transplantation"},{"key":"R25-19-20210129","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"R26-19-20210129","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/00007890-200005270-00019","article-title":"Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management.","volume":"69","author":"Hong","year":"2000","journal-title":"Transplantation"},{"key":"R27-19-20210129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1034\/j.1399-0012.2000.140201.x","article-title":"Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity.","volume":"14","author":"Kahan","year":"2000","journal-title":"Clin Transplant"},{"key":"R28-19-20210129","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1399-0012.2004.00253.x","article-title":"Dyslipidemia during sirolimus therapy in patients after liver transplantation.","volume":"18","author":"Kniepeiss","year":"2004","journal-title":"Clin Transplant"},{"key":"R29-19-20210129","doi-asserted-by":"crossref","first-page":"B101","DOI":"10.1016\/S0149-2918(00)89027-X","article-title":"Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.","volume":"22","author":"MacDonald","year":"2000","journal-title":"Clin Ther"},{"key":"R30-19-20210129","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/01.TP.0000128628.31556.B1","article-title":"A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications.","volume":"78","author":"Montalbano","year":"2004","journal-title":"Transplantation"},{"key":"R31-19-20210129","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(95)92534-1","article-title":"Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"R32-19-20210129","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00007890-199604150-00008","article-title":"A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.","volume":"61","year":"1996","journal-title":"Transplantation"},{"key":"R33-19-20210129","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00007890-199908150-00011","article-title":"Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.","volume":"68","year":"1999","journal-title":"Transplantation"},{"key":"R34-19-20210129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00007890-199701150-00008","article-title":"Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups.","volume":"63","author":"Halloran","year":"1997","journal-title":"Transplantation"},{"key":"R35-19-20210129","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1053-2498(01)00335-7","article-title":"Mycophenolate mofetil decreases antibody production after cardiac transplantation.","volume":"21","author":"Rose","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"R36-19-20210129","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/jlts.2001.23356","article-title":"A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients.","volume":"7","author":"Wiesner","year":"2001","journal-title":"Liver Transpl"},{"key":"R37-19-20210129","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1016\/S0041-1345(98)01434-1","article-title":"Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation.","volume":"30","author":"Reis","year":"1998","journal-title":"Transplant Proc"},{"key":"R38-19-20210129","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/bjo.82.6.700","article-title":"Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model.","volume":"82","author":"Reis","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"R39-19-20210129","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action.","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"R40-19-20210129","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/S0041-1345(02)03538-8","article-title":"Mechanisms of action of mycophenolate mofetil in preventing chronic rejection.","volume":"34","author":"Allison","year":"2002","journal-title":"Transplant Proc"},{"key":"R41-19-20210129","first-page":"1659","article-title":"Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and Bcell purine synthesis.","volume":"22","author":"Morris","year":"1990","journal-title":"Transplant Proc"},{"issue":"Suppl 1","key":"R42-19-20210129","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1007\/BF02343060","article-title":"Central corneolimbal transplantation under systemic ciclosporin A cover for severe limbal stem cell insufficiency.","volume":"234","author":"Sundmacher","year":"1996","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R43-19-20210129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-2008-1045885","article-title":"[Perforating keratoplasty in endogenous eczema. An indication for systemic cyclosporin A\u2014a retrospective study of 18 patients].","volume":"201","author":"Reinhard","year":"1992","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"R44-19-20210129","first-page":"224","article-title":"[Postoperative course after keratoplasty].","volume":"80","author":"Sundmacher","year":"1983","journal-title":"Fortschr Ophthalmol"},{"key":"R45-19-20210129","first-page":"584","article-title":"[Suture technique for perforating keratoplasty (author\u2019s transl)].","volume":"169","author":"Hoffmann","year":"1976","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"R46-19-20210129","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1001\/archopht.1981.03930010599002","article-title":"Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment.","volume":"99","author":"Alldredge","year":"1981","journal-title":"Arch Ophthalmol"},{"key":"R47-19-20210129","first-page":"14","article-title":"[Clinical types of immunologic transplant reactions following perforating keratoplasty].","volume":"87","author":"Pleyer","year":"1990","journal-title":"Fortschr Ophthalmol"},{"key":"R48-19-20210129","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"R49-19-20210129","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/eye.1995.99","article-title":"Systemic cyclosporine in high-risk keratoplasty: long-term results.","volume":"9","author":"Hill","year":"1995","journal-title":"Eye"},{"key":"R50-19-20210129","first-page":"432","article-title":"Six years\u2019 experience with systemic cyclosporin A prophylaxis in high-risk perforating keratoplasty patients. A retrospective study.","volume":"1","author":"Sundmacher","year":"1992","journal-title":"Ger J Ophthalmol"},{"key":"R51-19-20210129","doi-asserted-by":"crossref","first-page":"193S","DOI":"10.1016\/S0041-1345(03)00234-3","article-title":"Sirolimus in liver transplantation.","volume":"35","author":"Trotter","year":"2003","journal-title":"Transplant Proc"},{"key":"R52-19-20210129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2143\/AC.60.2.2005038","article-title":"Right atrial thrombosis in a heart transplant recipient after initiation of sirolimus.","volume":"60","author":"Vanderheyden","year":"2005","journal-title":"Acta Cardiol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003246-200604000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:13:07Z","timestamp":1785856387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200603150-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,15]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.tp.0000191291.71003.1b","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3,15]]}}}